<DOC>
	<DOCNO>NCT00707642</DOCNO>
	<brief_summary>The purpose Phase 1 trial evaluate clinical safety HBV-002 vaccine healthy adult .</brief_summary>
	<brief_title>Safety Study HBV-002 West Nile Vaccine Healthy Adults</brief_title>
	<detailed_description>West Nile virus emerge infectious disease U.S. worldwide identify CDC significant public health risk . Since introduction West Nile virus U.S. 1999 , annual outbreak cause severe fatal encephalitis human equines death variety species feral bird throughout U.S. part Canada . In addition , recent finding show evidence West Nile virus human equine infection several country tropical America . The virus find bird population 48 state continental U.S , human case West Nile disease document 45 state District Columbia . To date , approve commercial vaccine available prevention West Nile virus disease human .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Satisfactory medical assessment clinically significant relevant abnormality ( medical history , physical examination , vital sign , ECG , clinical laboratory evaluation [ hematology , biochemistry , urinalysis ] ) Body weight must 10 % 20 % ideal weight height frame size accord 1999 Metropolitan Life table Current active infection process include URI influenza Positive serum test HIV , Hepatitis B surface antigens and/or Hepatitis C antibodies History infection , serologic evidence screen test , prior flavivirus infection ( include virus : West Nile , 4 dengue serotypes , yellow fever ( YF ) , Japanese encephalitis ( JE ) Subject reside flavivirus ( West Nile , 4 dengue serotypes , YF , JE ) endemic area history receipt Yellow Fever Japanese encephalitis virus vaccine History alcohol substance abuse within 1 year screening Use corticosteroid immunosuppressive drug within 30 day screen ( Use topical nasal corticosteroid exclude . ) Any confirm suspected immunosuppressive immunodeficient condition Administration immunoglobulins within three month first vaccination plan study period Receipt vaccines investigational nonregistered product HBV002 within 30 day prior screen plan receipt throughout study . Receipt another study vaccine within 30 day prior screen Receipt blood product within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>West Nile Virus</keyword>
	<keyword>West Nile Vaccine</keyword>
	<keyword>West Nile virus disease</keyword>
	<keyword>Hawaii Biotech</keyword>
</DOC>